UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported):  March 2, 2005

 

Chiron Corporation

(Exact name of registrant as specified in its charter)

 

Delaware

 

0-12798

 

94-2754624

(State or other
jurisdiction of
incorporation)

 

(Commission
File Number)

 

(IRS Employer
Identification No.)

 

 

 

 

 

4560 Horton Street, Emeryville, CA

 

94608

(Address of principal executive offices)

 

(Zip Code)

 

 

 

 

 

Registrant’s telephone number, including area code (510) 655-8730

 

 

 

 

 

N/A

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 


 

Item 8.01.                                          Other Events

 

On March 2, 2005, Chiron Corporation issued a press release announcing its receipt of a notice from the UK Medicines and Healthcare products Regulatory Agency (MHRA) that the agency has lifted the license suspension for Chiron’s Liverpool manufacturing facility, which produces FLUVIRIN® influenza virus vaccine.

 

A copy of Chiron’s press release is attached hereto as Exhibit 99.1.

 

Item 9.01                                             Financial Statements and Exhibits

 

(c)                                  Exhibits

 

99.1                                                                           Press release issued on March 2, 2005.

 

2


 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

 

 

CHIRON CORPORATION

 

 

 

 

(Registrant)

 

 

 

 

 

 

 

 

 

 

 

Date:

March 2, 2005

By:

/s/ Ursula B. Bartels

 

 

 

 

Ursula B. Bartels

 

 

 

 

Vice President and

 

 

 

 

General Counsel

 

 

3